J&J Unit to Sell Sylvant Rights to U.K. Drugmaker Eusa Pharma

(Bloomberg) -- A unit of U.S. health-care giant Johnson & Johnson has agreed to sell global rights to a treatment for a rare blood disorder to Britain’s Eusa Pharma.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.